Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
1.630
-0.020 (-1.21%)
Jul 30, 2026, 2:55 PM EDT - Market open

Neumora Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-223.08-241.16-263.46-252.1-135.87-237.32
Net Income
-222.39-236.93-243.79-235.93-130.9-237.31
Earnings Per Share
-1.33-1.45-1.53-3.63-4.81-10.84
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
147.07182.53307.58453.98371.88409.25
Total Debt
53.3755.011.855.238.442.05
Net Cash (Debt)
93.7127.52305.73448.75363.44407.2
Net Cash Growth
-62.28%-58.29%-31.87%23.47%-10.75%114.39%
Net Cash Per Share
0.560.781.926.9013.3618.60

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-193.4-206.44-182.94-163.28-114.9-75.42
Capital Expenditures
----0.12-0.51-0.82
Free Cash Flow
-193.4-206.44-182.94-163.4-115.41-76.24
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.